Evolent Health, Inc. (NYSE:EVH) Director Brendan B. Springstubb Purchases 5,000 Shares

Evolent Health, Inc. (NYSE:EVH) Director Brendan B. Springstubb bought 5,000 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The stock was acquired at an average cost of $8.75 per share, with a total value of $43,750.00. Following the transaction, the director now owns 11,842 shares of the company’s stock, valued at $103,617.50. This trade represents a 73.08 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Evolent Health Trading Up 2.4 %

Shares of EVH opened at $8.76 on Thursday. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -10.68 and a beta of 1.45. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. Evolent Health, Inc. has a 12-month low of $8.35 and a 12-month high of $34.84. The stock’s 50-day moving average price is $10.50 and its 200 day moving average price is $18.01.

Evolent Health (NYSE:EVH) last issued its earnings results on Thursday, February 20th. The technology company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.38 by ($0.35). Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. The business had revenue of $646.54 million for the quarter, compared to the consensus estimate of $650.92 million. As a group, research analysts predict that Evolent Health, Inc. will post 0.08 earnings per share for the current year.

Hedge Funds Weigh In On Evolent Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Covestor Ltd boosted its stake in shares of Evolent Health by 138.1% during the 3rd quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock worth $40,000 after buying an additional 826 shares during the last quarter. Pilgrim Partners Asia Pte Ltd acquired a new position in shares of Evolent Health during the 4th quarter worth about $26,000. R Squared Ltd acquired a new stake in Evolent Health in the 4th quarter valued at about $31,000. AlphaQuest LLC lifted its stake in Evolent Health by 21,650.0% in the 4th quarter. AlphaQuest LLC now owns 3,045 shares of the technology company’s stock valued at $34,000 after purchasing an additional 3,031 shares during the last quarter. Finally, Parkside Financial Bank & Trust lifted its stake in Evolent Health by 90.7% in the 4th quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company’s stock valued at $56,000 after purchasing an additional 2,358 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on EVH. JMP Securities reissued a “market outperform” rating and set a $12.00 price objective on shares of Evolent Health in a research report on Friday, February 14th. Citigroup reduced their price objective on Evolent Health from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Friday, January 10th. Barclays cut their target price on Evolent Health from $39.00 to $19.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Oppenheimer cut their target price on Evolent Health from $28.00 to $18.00 and set an “outperform” rating on the stock in a report on Friday, January 24th. Finally, Royal Bank of Canada cut their target price on Evolent Health from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Tuesday, January 14th. One analyst has rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $17.79.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.